Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer

Clinical Lung Cancer
Rodolfo BordoniAchim Rittmeyer

Abstract

The randomized phase III OAK (a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small-cell lung cancer [NSCLC] who have failed platinum-containing therapy) trial investigated the anti-programmed cell death ligand 1 (PD-L1) antibody atezolizumab for advanced or metastatic, previously treated, NSCLC. Atezolizumab significantly improved overall survival (OS) compared with docetaxel (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.62-0.87; P = .0003; median OS, 13.8 vs. 9.6 months, respectively). Patient-reported outcomes (PROs) were collected to evaluate disease-related symptoms and health-related quality of life (HRQoL) to support the finding of a survival benefit. The first 850 patients were randomized to receive atezolizumab (1200 mg every 3 weeks) or docetaxel (75 mg/m2 every 3 weeks). PROs were collected on day 1 of cycle 1, day 1 of every subsequent cycle, and at the end-of-treatment visit for patients who completed ≥ 1 baseline and 1 postbaseline PRO assessment. The European Organisation for the Research and Treatment of Cancer QoL questionnaire and lung cancer module were used to assess PROs. Atezolizumab delayed the time to deterioration (TTD) in physical func...Continue Reading

Citations

May 28, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckMark A Socinski
May 14, 2020·Expert Opinion on Drug Safety·Anna ManzoAlessandro Morabito
Feb 16, 2019·International Journal of Environmental Research and Public Health·Sabina Asensio-CuestaJuan M García-Gómez
Apr 9, 2020·Frontiers in Medicine·Thierry BerghmansAnne-Marie Dingemans
May 28, 2019·Journal of Medical Economics·Ariane K KawataHuamao M Lin
Jul 18, 2020·Journal of Patient-reported Outcomes·Sara Colomer-LahigueraManuela Eicher
Jan 14, 2021·Survey of Ophthalmology·Carmen Alba-Linero, Emilio Alba
Jan 25, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Martin ReckKenneth John O'Byrne
Jul 21, 2021·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Amélie AnotaVirginie Westeel
Aug 8, 2020·Bulletin du cancer·Elodie Coquan, Florence Joly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Silvia NovelloLUME-Lung 1 Study Group
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Martin ReckRichard J Gralla
© 2022 Meta ULC. All rights reserved